XML 50 R21.htm IDEA: XBRL DOCUMENT v3.24.1
Other Non-Financial Assets
 12 Months Ended
Dec. 31, 2023
Other Non-Financial Assets [Abstract]  
Other Non-Financial Assets Other Non-Financial Assets
(in millions €)December 31, 2023December 31, 2022
Deferred expenses313.2120.0
Sales tax receivable5.293.8
Prepayments related to CRO and CMO contracts—35.3
Other45.929.3
Total364.3278.4
Total current280.9271.9
Total non-current83.46.5
Deferred expenses mainly comprise prepayments for future expenses of €151.1 million (nil as of December 31, 2022) for the settlement fee of the European Commission to our collaboration partner and prepayments for our collaborations with OncoC4 Inc., Rockville, USA, €22.5 million (nil as of December 31, 2022), Ryvu Therapeutics S.A., Krakau, Poland, €15.7 million (€19.7 million as of December 31, 2022) and Medigene Immunotherapies GmbH, Planegg/Martinsried, €5.1 million (€9.4 million as of December 31, 2022). Prior year deferred expenses mainly comprise service contracts and insurance obligations.